Literature DB >> 35278097

An update on the development of concepts, diagnostic criteria, and challenging issues for neuroendocrine neoplasms across different digestive organs.

Anne Couvelard1, Jérôme Cros2.   

Abstract

Digestive neuroendocrine neoplasms (NENs) are a group of heterogeneous neoplasms found throughout the digestive tract, with different behaviour and genetic background. In the last few years, nomenclature and WHO/UICC classifications of digestive NENs have changed, and molecular classifications have emerged, especially in pancreatic locations. Increasing patho-molecular details are needed to diagnose the different categories of NEN, including the use of helpful immunohistochemical markers. In this review, we address these topics in three successive chapters. We first briefly review recent updates in classifications, discuss important grading and proliferating issues and advances in the molecular understanding of NEN. Then, we provide an update on diagnosis, including the most important differential diagnoses of NEN, with a focus on high-grade neoplasms and mixed tumours. Finally, we highlight a variety of currently used and next-generation predictive and prognostic biomarkers as well as biomarkers of tumour origin and describe some site specificities of gastrointestinal NEN. We specifically focus on biomarkers available to pathologists with the potential to change the way patients with NEN are diagnosed and treated.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biomarkers; Classification; Digestive neuroendocrine tumour; Neuroendocrine carcinoma

Mesh:

Year:  2022        PMID: 35278097     DOI: 10.1007/s00428-022-03306-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  115 in total

1.  Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors.

Authors:  Deepti Dhall; Richard Mertens; Catherine Bresee; Rugvedita Parakh; Hanlin L Wang; Marissa Li; Girish Dhall; Steven D Colquhoun; Delma Ines; Fai Chung; Run Yu; Nicholas N Nissen; Edward Wolin
Journal:  Hum Pathol       Date:  2011-09-19       Impact factor: 3.466

2.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification.

Authors:  Aurel Perren; Anne Couvelard; Jean-Yves Scoazec; Frederico Costa; Ivan Borbath; Gianfranco Delle Fave; Vera Gorbounova; David Gross; Ashley Grossma; Robert T Jense; Matthew Kulke; Kjell Oeberg; Guido Rindi; Halfdan Sorbye; Staffan Welin
Journal:  Neuroendocrinology       Date:  2017-02-11       Impact factor: 4.914

3.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.

Authors:  Mahul B Amin; Frederick L Greene; Stephen B Edge; Carolyn C Compton; Jeffrey E Gershenwald; Robert K Brookland; Laura Meyer; Donna M Gress; David R Byrd; David P Winchester
Journal:  CA Cancer J Clin       Date:  2017-01-17       Impact factor: 508.702

4.  Comparison of different anti-Ki67 antibody clones and hot-spot sizes for assessing proliferative index and grading in pancreatic neuroendocrine tumours using manual and image analysis.

Authors:  Roisin Owens; Elaine Gilmore; Victoria Bingham; Christopher Cardwell; Hilary McBride; Stephen McQuaid; Matthew Humphries; Paul Kelly
Journal:  Histopathology       Date:  2020-09-02       Impact factor: 5.087

5.  Bariatric Surgery Lowers the Risk of Major Cardiovascular Events.

Authors:  Andrew M Brown; Jie Yang; Xiaoyue Zhang; Salvatore Docimo; Aurora D Pryo; Konstantinos Spaniolas
Journal:  Ann Surg       Date:  2020-11-18       Impact factor: 13.787

6.  Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor.

Authors:  Federica Grillo; Manuela Albertelli; Maria Pia Brisigotti; Tiziana Borra; Mara Boschetti; Roberto Fiocca; Diego Ferone; Luca Mastracci
Journal:  Neuroendocrinology       Date:  2015-08-25       Impact factor: 4.914

7.  High-grade progression confers poor survival in pancreatic neuroendocrine tumors.

Authors:  Johan Botling; Angela Lamarca; Duska Bajic; Olov Norlén; Vincent Lönngren; Josefin Kjaer; Barbro Eriksson; Staffan Welin; Per Hellman; Guido Rindi; Britt Skogseid; Joakim Crona
Journal:  Neuroendocrinology       Date:  2019-10-29       Impact factor: 4.914

Review 8.  Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis.

Authors:  Marta Tellez-Gabriel; Benjamin Ory; Francois Lamoureux; Marie-Francoise Heymann; Dominique Heymann
Journal:  Int J Mol Sci       Date:  2016-12-20       Impact factor: 5.923

9.  Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms.

Authors:  Francesco Panzuto; Noemi Cicchese; Stefano Partelli; Maria Rinzivillo; Gabriele Capurso; Elettra Merola; Marco Manzoni; Eugenio Pucci; Elsa Iannicelli; Emanuela Pilozzi; Michele Rossi; Claudio Doglioni; Massimo Falconi; Gianfranco Delle Fave
Journal:  PLoS One       Date:  2017-06-23       Impact factor: 3.240

10.  A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms.

Authors:  M S Khan; T V Luong; J Watkins; C Toumpanakis; M E Caplin; T Meyer
Journal:  Br J Cancer       Date:  2013-04-11       Impact factor: 7.640

View more
  1 in total

Review 1.  The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Shuaishuai Xu; Chanqi Ye; Ruyin Chen; Qiong Li; Jian Ruan
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.